Abstract：【Objective】 To investigate the relationship of clinical stage with osteoporosis and growth factors in patients with type 2 diabetic nephropathy (DN). 【Methods】 A total of 200 patients with type 2 diabetic nephropathy, who received treatment in our hospital, were selected as the observation group. According to the value of albumin excretion rate (UAE), patients were divided into group A (normal albuminuria, UAE<20 μg/min) , group B (microalbuminuria, UAE 20-200 μg/min), group C (large amount of albuminuria, UAE>200 μg/min) and group D (end-stage renal failure, GFR <10 mL/min). In the same time period, 50 healthy volunteers were enrolled as the control group. The levels of osteoporosis and growth factor-related indicators were evaluated. 【Results】 The bone mineral density and mineral content of both cancellous and cortical bones in the observation group were lower than those in the control group (P<0.05). The T value of the cancellous bone and the cortical bone were higher than those of the control group (P<0.05). There were significant differences in bone mineral density and growth factor indicators among the subgroups of the observation group (P<0.05). The cancellous and cortical bone mineral density and mineral content in group D were lower than those in group A, B and C, while the T value of the cancellous bone and the cortical bone were higher than those in group A, B and C (P<0.05). The levels of FGF-23 and IL-6 in the observation group were higher than those in the control group, and IGF-Ⅱ, EGF and TGF-βlevels were lower than those in the control group (P<0.05). The levels of FGF-23 and IL-6 in group D were higher than those in group A, B and C, and IGF-Ⅱ, EGF and TGF-βwere lower than those in group A, B and C (P<0.05). The levels of FGF-23 and IL-6 in group C were higher than those in group A and B, and IGF-Ⅱ, EGF and TGF-βwere lower than those in group A and B (P<0.05). 【Conclusion】 The severity of DN in patients with type 2 diabetes is closely related to osteoporosis and growth factors. The occurrence of osteoporosis in DN patients may be related to growth factors.
韩冬梅, 毛维维, 巩伟伟, 李晗, 周蒨. 2型糖尿病肾病患者临床分期与骨质疏松及生长因子的关系[J]. 医学临床研究, 2020, 37(9): 1297-1299.
HAN Dong-mei, MAO Wei-wei, GONG Wei-wei, et al. Relationship of Clinical Stage in Patients with Type 2 Diabetic Nephropathy with Osteoporosis and Growth Factors. JOURNAL OF CLINICAL RESEARCH, 2020, 37(9): 1297-1299.
[1] Zhong N, Zhang Y, Pu X, et al. Microangiopathy is associated with bone loss in female type 2 diabetes mellitus patients[J].Diabet Vasc Dis Res,2018,15(5):433-441.
[2] 麻红艳,叶山东.老年男性2型糖尿病患者骨质疏松相关因素分析[J].中华疾病控制杂志,2017,21(7):688-692.
[3] 谢兴文,李建国,黄晋, 等.血管内皮生长因子防治骨质疏松的研究进展[J].中国骨质疏松杂志,2019,25(7):1030-1033.
[4] 中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].糖尿病临床,2016,10(6):243-253.
[5] Zhao Z. Correlation analysis of urine proteins and inflammatory cytokines with osteoporosis in patients with diabetic nephropathy[J].J Musculoskelet Neu Int,2018,18(3):348-353.
[6] Thomas GN, Critchley JA, Tomlinson B, et al. Peripheral vascular disease in Type 2 diabetic Chinese patients: associations with metabolic indices, concomitant vascular disease and genetic factors[J].Diabet Med,2003,20(12):988-995.
[7] Levey AS, Coresh J. Chronic kidney disease[J].Lancet,2012,379(9811):165-180.
[8] 蒋林博,宋敏,刘小钰, 等.结合力生长因子探讨骨肉不相亲理论与骨质疏松症[J].中国骨质疏松杂志,2018,24(3):385-388,405.
[9] Yamamoto M1, Sugimoto T. Advanced Glycation End Products, Diabetes, and Bone Strength[J].Curr Osteoporos Rep,2016,14(6):320-326.
2020, Vol. 37 
